UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): ~~April~~May 1412, 2011

JIANGBO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Florida

(State or other jurisdiction of incorporation)

001-34763		65-1130026
(Commission File Number)		(IRS Employer Identification No.)

25 Haihe Road, Laiyang Economic Development

Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200

(Address of principal executive offices and zip code)

(0086) 535-7282997

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 45.0102 ~~Changes~~Departure inof ~~Registrant’s~~Directors ~~Certifying~~or ~~Accountant~~Certain Officers; Election of Directors; appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 16, 2011, Jiangbo Pharmaceuticals, Inc. (the “Company”) ~~was~~issued ~~notified~~a press release announcing that, effective ~~April~~May 1412, 2011, the ~~practice~~Board of ~~Bernstein~~Directors &of ~~Pinchuk LLP (“B&P”),~~ the Company’s ~~independent~~appointed ~~registered~~Ms. ~~public~~Ziling ~~accounting~~Sun ~~firm,~~as ~~entered~~the ~~into~~Interim aChief ~~joint~~Financial ~~venture~~Officer ~~agreement~~of ~~with~~the ~~Marcum~~Company ~~LLP and formed Marcum Bernstein & Pinchuk LLP (“Marcum BP”) in a transaction pursuant~~ to ~~which~~fill ~~B&P merged its China operations into Marcum BP and certain of~~ the ~~professional~~vacancy ~~staff~~created ofby ~~B&P~~resignation ~~joined Marcum BP as employees~~ of ~~Marcum BP~~Ms. ~~Accordingly,~~Elsa ~~effective~~Sung ~~April 14, 2011, B&P resigned~~ as the ~~Company's~~Chief ~~independent~~Financial ~~registered~~Officer ~~public~~of ~~accounting firm and Marcum BP became~~ the Company's ~~independent~~effective ~~registered~~March ~~public~~31, ~~accounting firm~~2011. ~~Marcum BP is currently registered with the Public Company Accounting and Oversight Board (PCAOB).~~

~~This~~Ms. ~~change~~Sun, inage ~~the~~48, ~~Company's~~has ~~independent~~been ~~registered~~serving ~~public~~as ~~accounting~~an ~~firm~~accountant ~~was~~at ~~approved~~Laiyang byJiangbo Pharmaceuticals, Co., Ltd., a limited liability company organized under the ~~Audit~~laws ~~Committee~~of People’s Republic of China and controlled by the Company's ~~Board~~through ofcontractual ~~Directors~~arrangements on(“Laiyang ~~April~~Jiangbo”) 19since January 2010. From October 2007 to October 2009, ~~2011~~she served as a financial controller at Yantai Human Special Vehicle Co., ~~Marcum~~Ltd. BPwhere she was ~~engaged~~responsible asfor overall financial accounting. From September 1997 to September 2007, Ms. Sun worked in the accounting department of Yantai Automotive Manufacturing Company's ~~independent~~where ~~registered~~she ~~public~~was responsible for the overall financial accounting. ~~firm~~Ms. onSun ~~April~~received 19her associate degree in political science from Yantai Normal College in July 1997. She also received her Intermediate Accountant Certificate in 2006, and passed all required subjects of the Professional Stage of the National Uniform CPA Examination of P.R. China in 2011.

~~During~~Ms. ~~the~~Sun ~~Company’s~~has ~~most~~entered ~~two~~into ~~recent~~an ~~fiscal~~Employment ~~years~~Contract, ~~ended~~dated ~~June~~May 3012, ~~2010~~2011 ~~and~~(the ~~2009 and through April 20~~“Contract”), ~~2011,~~with the Company ~~did~~and ~~not~~Laiyang ~~consult~~Jiangbo. ~~with~~The ~~Marcum~~Contract BPprovides onfor ~~(i) the~~a ~~application~~monthly salary of ~~accounting~~RMB5,000 ~~principles~~and tocontinues for a ~~specified~~term ~~transaction,~~of ~~either~~six ~~completed~~months. orThe ~~proposed,~~Contract orcan ~~the~~be ~~type~~terminated ofby ~~audit~~30-days ~~opinion~~advance ~~that~~notice ~~may~~by beeither ~~rendered~~party. onThe ~~the~~Contract ~~Company’s~~can ~~financial~~be ~~statements,~~automatically ~~and~~renewed ~~Marcum~~unless BPeither ~~did~~party ~~not~~gives ~~provide~~30-days ~~either~~advance a written ~~report~~notice orto ~~oral~~the ~~advice~~other parties prior to the ~~Company~~expiration of the term of the Contract of that ~~was~~party’s anintention ~~important~~to ~~factor~~renew ~~considered~~the byContract. Pursuant to the ~~Company~~Contract, inMs. ~~reaching~~Sun is entitled to a ~~decision~~total asof totwenty ~~any~~five ~~accounting,~~paid ~~auditing~~vacation, orsick ~~financial~~and ~~reporting~~personal ~~issue;~~days orduring ~~(ii) the~~each ~~subject~~calendar ofyear ~~any~~and ~~disagreement,~~social assecurity ~~defined~~insurance in ~~Item 304~~accordance ~~(a)(1)(iv)~~with Chinese laws and regulations. A copy of ~~Regulation S-K~~Ms. Sun’s Contract is filed herewith as Exhibit 10.1 and ~~the~~is ~~related~~incorporated ~~instructions,~~herein orto athis ~~reportable~~Current ~~event~~Report ~~within~~on Form 8-K by reference. A copy of the ~~meaning~~press ~~set~~release ~~forth~~is inalso ~~Item 304(a)(~~filed herewith as Exhibit 99.1~~)(v)~~ ofto ~~Regulation S-K~~this current report and is incorporated by reference.

B&P was engaged by the Company on March 30, 2011 and as a result did not prepare the audits of the Company’s financial statements for the fiscal years ended June 30, 2010 and 2009 and through the date of this Current Report. As a result, in connection with the audits of the Company’s financial statements for the fiscal years ended June 30, 2010 and 2009 and through the date of this Current Report, there were: (i) no disagreements between the Company and B&P on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of B&P, would have caused B&P to make reference to the subject matter of the disagreement in their reports on the Company’s financial statements for such years, and (ii) no reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

The Company has provided B&P a copy of the disclosures in this Form 8-K and has requested that B&P furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not B&P agrees with the Company’s statements in this Item 4.01(a). A copy of the letter dated April 20, 2011, furnished by B&P in response to that request is filed as Exhibit 16.1 to this Form 8-K.

Item 9.01

Financial Statements and Exhibits.

Exhibit No.	Description
16.1	Letter of Bernstein & Pinchuk LLP to the SEC, dated April 20, 2011.
10.1	Employment Contract between Ms. Ziling Sun, the Company and Laiyang Jiangbo, dated May 12, 2011.
99.1	Press Release dated May 16, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JIANGBO PHARMACEUTICALS, INC.

	By:	/s/ Jin Linxian
	Name:	Jin Linxian
	Title:	Chief Executive Officer

Dated: ~~April~~May 2016, 2011

Filing Compare · Jiangbo Pharmaceuticals, Inc.